DVT complete diagnostic approach resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 43: Line 43:




==Table==
{{Family tree/start}}
 
{{familytree  | | | | | | | | | | | | | A01 | | | | | | | | | | A01= <div style="float: left; text-align: left; width: 18em; padding:1em;">'''Identify cardinal signs and symptoms that increase the pretest probability of pericarditis'''<br>
{| style="background: #FFFFFF;"
❑ [[Tachycardia]] <br> ❑ [[Hypotension]]<br>❑ [[Loss of consciousness]]<br>❑ Severe [[dyspnea]]<br>
| valign=top |
</div>}}
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
{{familytree  | | | | | | | | | | | | | |!| | | | | | | }}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center colspan="2"| {{fontcolor|#FFF|Management of focal atrial tachycardia}}
{{familytree  | | | | | | | | | | | | | A01 | | | | | | | | | | A01= <div style="float: left; text-align: left; width: 18em; padding:1em;">'''Determine if the patient is unstable'''<br></div>}}
|-
{{familytree  | | | | | | | | | | |,|-|-|^|-|-|.| | | | |}}
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Acute treatment'''''
{{familytree  | | | | | | | | | | B01 | | | | B02 | | | | B01=<div style=" background: #F60A0A"> {{fontcolor|#F8F8FF|'''Unstable patient'''}}</div> | B02= '''Stable patient'''|border=0}}
|-
{{familytree  | | | | | | | | | | |!| | | | | |!| | | | }}
| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left | '''''Conversion in hemodynamically unstable patient'''''|| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left|▸ '''''[[DC cardioversion]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])
{{familytree  | | | | | | | | | | A01 | | | | |!| | | | | A01= <div style="float: left; text-align: left; width: 18em; padding:1em;">'''Suspect cardiac tamponade'''<br></div>}}
|-
{{familytree  | | | | | | | | | | |!| | | | | |!| | | | }}
| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left | '''''Conversion in hemodynamically stable patient'''''|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Adenosine]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR> ▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Beta blocker]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Amiodarone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Sotalol]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Procainamide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Flecainide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Propafenone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])
{{familytree  | | | | | | | | | | C01 | | | | C02 | | | | C01=<div style=" background: #F60A0A; text-align: left; width: 22em"> {{fontcolor|#F8F8FF|❑ Look for Beck's triad <br> ❑ Pulsus paradoxus <br> ❑ Muffled heart sounds<br> ❑ Hypotension}}</div> |border=red|C02=Continue with complete diagnostic approach}}
|-
{{familytree  | | | | | | | | | | |!| | | | | | | | | | }}
| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left | '''''Rate control'''''|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Beta blocker]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Digoxin]]''''' ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence C]])
{{familytree  | | | | | | | | | | E01 | | | | | | | | | E01=<div style=" background: #F60A0A; text-align: left"> {{fontcolor|#F8F8FF| ❑ Assess airway, breathing, and circulation ([[ABC (medical)|<span style="color:white;">ABC</span>]]) <br> ❑ Administer [[oxygen|<span style="color:white;"> oxygen </span>]] if necessary }} </div> | C02=<div style="float: left; text-align: left; width: 15em; padding:1em;">  '''[[Aortic stenosis resident survival guide#Complete Diagnostic Approach to Aortic Stenosis|Continue with the diagnostic approach]]''' }}</div> | border=0}}
|-
{{familytree  | | | | | | | | | | |!| | | | | | | | | | }}
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Prophylactic therapy'''''
{{familytree  | | | | | | | | | | F01 | | | | | | | | | F01=<div style=" background: #F60A0A; text-align: left; width: 22em"> {{fontcolor|#F8F8FF| ❑ Treat the cardiac tamponade <br>
|-
:: ❑ Resuscitate the patient<br>
| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left| '''''Recurrent symptomatic [[atrial tachycardia]]'''''|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR> ▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Disopyramide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Amiodarone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Sotalol]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Flecainide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Propafenone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])
:: ❑ Bedside echo<br>
|-
:: ❑ Urgent pericardiocentesis<br>
| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left| '''''Asymptomatic or symptomatic incessent [[atrial tachycardia]]'''''|| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left |▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])
:: ❑ Expert consultation
|-
}}</div> |border=red}}
|style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left| '''''Asymptomatic and non-sustained [[atrial tachycardia]]'''''|| style="padding: 0 5px; font-size: 90%; background: #DCDCDC;" align=left |▸ '''''No therapy''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>
{{Family tree/end}}
▸ '''''[[Catheter ablation]] ''''' ([[ACC AHA guidelines classification scheme|Class III, level of evidence C]])
|-
|}
 
{| style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center colspan="2"| {{fontcolor|#FFF|Management of focal and nonparoxysmal junctional tachycardia}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''[[Focal junctional tachycardia]]'''''
|-
|style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Amiodarone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Sotalol]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Flecainide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Propafenone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Non paroxysmal junctional tachycardia'''''
|-
|style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Reverse [[digitalis toxicity]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''AND''<BR>▸ '''''Correct [[hypokalemia]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''AND''<BR>▸ '''''Treat [[myocardial ischemia]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Calcium channel blockers]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])
|}
 
{| style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center colspan="2"| {{fontcolor|#FFF|Management of recurrent AVNRT}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''[[AVNRT]] with hemodynamic intolerance'''''
|-
|style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Amiodarone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Sotalol]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Flecainide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Propafenone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])
|-
|style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Recurrent symptomatic [[AVNRT]]'''''
|-
|style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Digoxin]]''''' ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence C]])
|-
|style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Recurrent [[AVNRT]] unresponsive to [[beta blockers]] and [[calcium channel blockers]],<br> patient not desiring [[radiofrequency ablation]]'' '''
|-
|style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Flecainide]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Propafenone]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Sotalol]]''''' ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence B]])<BR>''OR''<BR> ▸ '''''[[Amiodarone]]''''' ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence C]])
|-
|style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Single episode of [[AVNRT]] or infrequent [[AVNRT]]<br> in patients desiring complete control of arrhythmia'' '''
|-
|style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])
|-
 
|style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Documented [[PSVT]] with only dual AV nodal pathways OR<br> single echo beats documented during electrophysiological study AND<br> no other cause of arrhythmia identified'' '''
|-
|style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Flecainide]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Propafenone]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])
|-
|style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center colspan="2" | '''''Infrequent, well tolerated [[AVNRT]]'' '''
|-
|style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''No therapy''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Vagal maneuvers]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''Pill in the pocket''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])<BR>''OR''<BR>▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])
|-
|}
 
{| style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center colspan="2"| {{fontcolor|#FFF|Management of inappropriate sinus tachycardia}}
|-
|style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Beta blockers]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Verapamil]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Diltiazem]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence C]])<BR>''OR''<BR>▸ '''''[[Catheter ablation]]''''' ([[ACC AHA guidelines classification scheme|Class I, level of evidence B]])
|-
|}

Revision as of 14:44, 28 March 2014

Probability of infective endocaritis Characteristics
Definite diagnosis by pathological criteria❑ Microorganisms demonstrated by culture or histological examination
of a vegetation, OR
❑ Pathological lesions; vegetation or intracardiac abscess confirmed by histological
examination showing active endocarditis
Definite diagnosis by clinical criteria❑ 2 major criteria; OR

❑ 1 major criterion and 3 minor criteria; OR

❑ 5 minor criteria
Possible diagnosis❑ 1 major criterion and 1 minor criterion; OR
❑ 3 minor criteria
Rejected diagnosis❑ Firm alternative diagnosis explaining evidence of IE, OR

❑ Resolution of IE syndrome with antibiotic therapy for 4 days, OR
❑ No pathological evidence of IE at surgery or autopsy, with antibiotic therapy for 4 days, OR

❑ Does not meet criteria for possible IE as above



Criteria Definite Infective Endocarditis According to Modified Duke Criteria
Pathological Criteria
Microorganisms demonstrated by culture or histological examination of a vegetation
Pathological lesions; vegetation or intracardiac abscess confirmed by histological examination showing active endocarditis
Clinical Criteria
2 major criteria; or
1 major criterion and 3 minor criteria; or
5 minor criteria
Possible IE
1 major criterion and 1 minor criterion; or
3 minor criteria
Rejected
Firm alternative diagnosis explaining evidence of IE; or
Resolution of IE syndrome with antibiotic therapy for 4 days; or
No pathological evidence of IE at surgery or autopsy, with antibiotic therapy for 4 days; or
Does not meet criteria for possible IE as above


| border=0}}
 
 
 
 
 
 
 
 
 
 
 
 
Identify cardinal signs and symptoms that increase the pretest probability of pericarditis

Tachycardia
Hypotension
Loss of consciousness
❑ Severe dyspnea

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Determine if the patient is unstable
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unstable patient
 
 
 
Stable patient
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Suspect cardiac tamponade
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Look for Beck's triad
❑ Pulsus paradoxus
❑ Muffled heart sounds
❑ Hypotension
 
 
 
Continue with complete diagnostic approach
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Assess airway, breathing, and circulation (ABC)
❑ Administer oxygen if necessary
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Treat the cardiac tamponade
❑ Resuscitate the patient
❑ Bedside echo
❑ Urgent pericardiocentesis
❑ Expert consultation